Want to join the conversation?
$REGN, which competes with $AMGN & Novartis AG, said that 4Q15 EYLEA US net sales grew 44% YoverY to $746MM. The market share of treated eyes for EYLEA and DME is roughly double that of ranibizumab and similar to that for off-label bevacizumab. Praluent net sales were $7MM, which understates actual physician and patient demand.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!